PINOXEPIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H27ClN2O2
Molecular Weight	398.926
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCN1CCN(CC\C=C2\C3=CC=CC=C3COC4=CC=C(Cl)C=C24)CC1

InChI

InChIKey=RAAHIUIRJUOMAU-MPUCSWFWSA-N

InChI=1S/C23H27ClN2O2/c24-19-7-8-23-22(16-19)21(20-5-2-1-4-18(20)17-28-23)6-3-9-25-10-12-26(13-11-25)14-15-27/h1-2,4-8,16,27H,3,9-15,17H2/b21-6-

HIDE SMILES / InChI

Molecular Formula	C23H27ClN2O2
Molecular Weight	398.926
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5237376 | https://www.ncbi.nlm.nih.gov/pubmed/4160265 | https://www.ncbi.nlm.nih.gov/pubmed/5255181 | Iversen, L. (2012) Handbook of Psychopharmacology, retrieved from: https://books.google.ru/books?id=C97OBgAAQBAJ | Elks, J. (2014) The Dictionary of Drugs: Chemical Data, page 984, retrieved from: https://books.google.ru/books?id=0vXTBwAAQBAJ

Pinoxepin belongs to the dibenzoxepine series of drugs which are characterized by a 6-7-6 tricyclic nuclear structure. Clinical studies indicated that pinoxepin was a potent antipsychotic-sedative equally effective to chlorpromazine and thioridazine. Pinoxepin in studies with chronic schizophrenic patients displayed useful effects on behavior without unduly prominent side effects. In doses above 300 mg seizures are reported and more frequent changes in liver-function tests were noted than with standard drug, but below 300 mg pinoxepin was found to have side effects similar to chlorpromazine and marked sedative effects.

Approval Year

PubMed

Title	Date	PubMed
Comparison of perphenazine and P-5227 in chronic schizophrenics: clinical and EEG effects.	1969-05-01	5255181
Comparison of P-5227 and thioridazine in chronic schizophrenic patients.	1967-09-01	5237376
Pinoxepin vs. chlorpromazine: a double-blind comparison.	1967-08	4962467
Effects of pinoxepin and imipramine on the mesencephalic reticular formation and amygdaloid complex in the cat: neurophysiological and clinical correlations in human subjects.	1967-07	4963166
A PRELIMINARY STUDY OF P-5227, a new active tricyclic antipsychotic agent.	1966-10	4961022
P-5227: an active dibenzoxepine antipsychotic.	1966-05	4956386
P-5227: a 6-7-6 tricyclic antipsychotic compound.	1966-05	4160265

Sample Use Guides

In Vivo Use Guide

Daily dosage: 50 mg - 1st week, 100mg - 2nd week, 150 mg - 3rd week, 200 mg - 4th week, 250 mg - 5th week, 250-400 mg - 6-10th weeks.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:18 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:18 GMT 2025`
Record UNII	Y3YKO9X8N8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(Z)-4-(3-(2-CHLORODIBENZ(B,E)OXEPIN-11-(6H)-YLIDENE)PROPYL)-1-PIPERAZINEETHANOL

Preferred Name

English

PINOXEPIN

Official Name

English

pinoxepin [INN]

Common Name

English

1-PIPERAZINEETHANOL, 4-(3-(2-CHLORODIBENZ(B,E)OXEPIN-11(6H)-YLIDENE)PROPYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66883